Europe Pharmaceutical Cold Chain Logistics Market By Product, Temperature Type and Mode of Transportation: Country Opportunity Analysis and Industry Forecast, 2023 – 2032
The Europe pharmaceutical cold chain logistics market size was esteemed at $6,700.00 million in 2022 and is estimated t%li%reach $12,307.51 million by 2032, exhibiting a CAGR of 6.5% from 2023 t%li%2032.
A cold chain is a fundamental part of pharma shipments and transits. It is often considered a temperature-controlled supply system used t%li%store and transport perishable products, such as vaccines, biologics, and drugs. This chain must preserve a particular temperature range, often between 2°C and 8°C, t%li%preserve the safety, potency, and efficacy of pharmaceutical products through the entire supply chain, from manufacturing and storage t%li%transportation and distribution. Aside from directing processes, manufacturers, distributors, and healthcare providers benefit from technological innovations and developments t%li%preserve the quality and integrity of pharmaceutical products and, consequently, ensure the safety of the consumers in need.
The integration of radiofrequency identification technology (RFID), AI, and blockchain technology in pharmaceutical cold-chain logistics is expected t%li%revolutionize the cold-chain logistics industry, making it more efficient and secure. RFID system for cold chain applications consists of a reader, a tag, and a sensor that communicate with one another via radi%li%transmission. If they have the right sensor and enough power, RFID tags can store a finite number of temperature measurements in addition t%li%an electronic product code (EPC) for logistics management purposes.
In addition, RFID technologies improve the performance of perishable supply chains through the device t%li%track the geographical position of individual packages, pallets, shipping containers, or trucks, which can be stationary or in movement during distribution. These technologies are used t%li%identify items through a unique EPC or other barcode and t%li%store real-time environmental data (including temperature), which is later transmitted, allowing corrective actions t%li%be taken before products are irrevocably damaged. The technology provides manufacturers the transparency in tracing and protecting throughout the product supply chain.
Rise in several refrigerated warehouses and expansion of the pharmaceutical sector, along with the government policies and initiatives t%li%promote cold chain logistics is expected t%li%drive the growth of the pharmaceutical cold chain logistics market. In addition, the constant development of machines and medicines due t%li%the rising number of approvals for pharmaceutical products in Europe fuels the growth of the aftermarket shock absorbers market. On the contrary, the rise in the number of products and services, from vaccines t%li%cell and gene therapies, requires cold chain handling and refrigerated warehouses are projected t%li%offer lucrative opportunities for the expansion of the market during the forecast period.
However, there is a concern about the high cost required for maintaining cold chain logistics, such as refrigerated storage facilities and transportation systems that poses a considerable challenge t%li%the growth of the market. This cost can act as a barrier for smaller pharmaceutical companies or those operating in developing regions. Further, temperature excursions or disruptions in the cold chain may result in the loss of valuable pharmaceutical products. This risk is especially significant for temperature-sensitive medications, vaccines, and biologics, leading t%li%financial losses and potential reputational damage for pharmaceutical companies. This is expected t%li%hamper the growth of Europe's pharmaceutical cold chain logistics market.
The European pharmaceutical cold chain logistics market is segmented int%li%product, temperature type, mode of transportation, and region.
A cold chain is a fundamental part of pharma shipments and transits. It is often considered a temperature-controlled supply system used t%li%store and transport perishable products, such as vaccines, biologics, and drugs. This chain must preserve a particular temperature range, often between 2°C and 8°C, t%li%preserve the safety, potency, and efficacy of pharmaceutical products through the entire supply chain, from manufacturing and storage t%li%transportation and distribution. Aside from directing processes, manufacturers, distributors, and healthcare providers benefit from technological innovations and developments t%li%preserve the quality and integrity of pharmaceutical products and, consequently, ensure the safety of the consumers in need.
The integration of radiofrequency identification technology (RFID), AI, and blockchain technology in pharmaceutical cold-chain logistics is expected t%li%revolutionize the cold-chain logistics industry, making it more efficient and secure. RFID system for cold chain applications consists of a reader, a tag, and a sensor that communicate with one another via radi%li%transmission. If they have the right sensor and enough power, RFID tags can store a finite number of temperature measurements in addition t%li%an electronic product code (EPC) for logistics management purposes.
In addition, RFID technologies improve the performance of perishable supply chains through the device t%li%track the geographical position of individual packages, pallets, shipping containers, or trucks, which can be stationary or in movement during distribution. These technologies are used t%li%identify items through a unique EPC or other barcode and t%li%store real-time environmental data (including temperature), which is later transmitted, allowing corrective actions t%li%be taken before products are irrevocably damaged. The technology provides manufacturers the transparency in tracing and protecting throughout the product supply chain.
Rise in several refrigerated warehouses and expansion of the pharmaceutical sector, along with the government policies and initiatives t%li%promote cold chain logistics is expected t%li%drive the growth of the pharmaceutical cold chain logistics market. In addition, the constant development of machines and medicines due t%li%the rising number of approvals for pharmaceutical products in Europe fuels the growth of the aftermarket shock absorbers market. On the contrary, the rise in the number of products and services, from vaccines t%li%cell and gene therapies, requires cold chain handling and refrigerated warehouses are projected t%li%offer lucrative opportunities for the expansion of the market during the forecast period.
However, there is a concern about the high cost required for maintaining cold chain logistics, such as refrigerated storage facilities and transportation systems that poses a considerable challenge t%li%the growth of the market. This cost can act as a barrier for smaller pharmaceutical companies or those operating in developing regions. Further, temperature excursions or disruptions in the cold chain may result in the loss of valuable pharmaceutical products. This risk is especially significant for temperature-sensitive medications, vaccines, and biologics, leading t%li%financial losses and potential reputational damage for pharmaceutical companies. This is expected t%li%hamper the growth of Europe's pharmaceutical cold chain logistics market.
The European pharmaceutical cold chain logistics market is segmented int%li%product, temperature type, mode of transportation, and region.
- Product
- Vaccines,
- Biologics,
- Specialty Medications
- Others.
- Type,
- Chilled
- Frozen
- Room Temperature
- Mode Of Transportation
- Railways
- Airways
- Roadways
- Waterways.
- Country
- France
- Germany
- Italy
- Spain
- UK
- Switzerland
- Ireland
- The Rest of Europe.
- Key players covered in the report
- A.P. Moller–Maersk
- DB Schenker
- DHL Group
- DSV
- Geodis
- H. Essers
- Kuehne + Nagel
- Movianto
- Sovereign
- VTS Transport & Logistics.
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s Five Forces Analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in number of refrigerated warehouses and expansion of the pharmaceutical sector
3.4.1.2. Government policies and initiatives to promote the cold chain logistics in the pharmaceutical sector
3.4.2. Restraints
3.4.2.1. Poor infrastructure and higher logistics costs
3.4.2.2. Environmental concerns regarding greenhouse gas emission
3.4.3. Opportunities
3.4.3.1. Surge in use of IT solutions & automated software for pharmaceutical cold chain logistics
3.4.3.2. Rise in demand for temperature-sensitive pharmaceutical drugs
3.5. COVID-19 Impact Analysis
3.6. Active Vs Passive Cold Chain Transportation
3.7. Importance of Active Vs Passive Cold Chain Transportation
3.7.1. Global Pharmaceutical Cold Chain Logistics Market, by Region, 2022-2032 ($Million)
3.8. Market Size and Forecast for Parcels, by Type, 2022-2032 ($Million)
3.9. Market Size and Forecast for Pallets, by Type, 2022-2032 ($Million)
CHAPTER 4: EUROPE PHARMACEUTICAL COLD CHAIN LOGISTICS MARKET, BY PRODUCT
4.1. Overview
4.2. Vaccines
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by country
4.3. Biologics
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by country
4.4. Specialty medications
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by country
4.5. Others
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by country
CHAPTER 5: EUROPE PHARMACEUTICAL COLD CHAIN LOGISTICS MARKET, BY TEMPERATURE TYPE
5.1. Overview
5.2. Chilled
5.2.1. Key market trends, growth factors, and opportunities
5.2.2. Market size and forecast, by country
5.3. Frozen
5.3.1. Key market trends, growth factors, and opportunities
5.3.2. Market size and forecast, by country
5.4. Room Temperature (15-25°C)
5.4.1. Key market trends, growth factors, and opportunities
5.4.2. Market size and forecast, by country
CHAPTER 6: EUROPE PHARMACEUTICAL COLD CHAIN LOGISTICS MARKET, BY MODE OF TRANSPORTATION
6.1. Overview
6.2. Railways
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country
6.3. Airways
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by region
6.4. Roadways
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by type
6.4.3. Market size and forecast, by region
6.5. Waterways
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by region
CHAPTER 7: EUROPE PHARMACEUTICAL COLD CHAIN LOGISTICS MARKET, BY COUNTRY
7.1. Overview
7.2. Europe
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. France
7.2.2.1.1. Market size and forecast, by Product
7.2.2.1.2. Market size and forecast, by Temperature Type
7.2.2.1.3. Market size and forecast, by Mode of Transportation
7.2.2.2. Germany
7.2.2.2.1. Market size and forecast, by Product
7.2.2.2.2. Market size and forecast, by Temperature Type
7.2.2.2.3. Market size and forecast, by Mode of Transportation
7.2.2.3. Italy
7.2.2.3.1. Market size and forecast, by Product
7.2.2.3.2. Market size and forecast, by Temperature Type
7.2.2.3.3. Market size and forecast, by Mode of Transportation
7.2.2.4. Spain
7.2.2.4.1. Market size and forecast, by Product
7.2.2.4.2. Market size and forecast, by Temperature Type
7.2.2.4.3. Market size and forecast, by Mode of Transportation
7.2.2.5. UK
7.2.2.5.1. Market size and forecast, by Product
7.2.2.5.2. Market size and forecast, by Temperature Type
7.2.2.5.3. Market size and forecast, by Mode of Transportation
7.2.2.6. Switzerland
7.2.2.6.1. Market size and forecast, by Product
7.2.2.6.2. Market size and forecast, by Temperature Type
7.2.2.6.3. Market size and forecast, by Mode of Transportation
7.2.2.7. Ireland
7.2.2.7.1. Market size and forecast, by Product
7.2.2.7.2. Market size and forecast, by Temperature Type
7.2.2.7.3. Market size and forecast, by Mode of Transportation
7.2.2.8. Rest of Europe
7.2.2.8.1. Market size and forecast, by Product
7.2.2.8.2. Market size and forecast, by Temperature Type
7.2.2.8.3. Market size and forecast, by Mode of Transportation
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Key player positioning ,2022
8.2. Competitive dashboard
8.2.1. Top winning strategies
CHAPTER 9: COMPANY PROFILES
9.1. A.P. MOLLER MAERSK
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. DB SCHENKER
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. DHL GROUP
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. DSV
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. GEODIS
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. H. ESSERS
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Key strategic moves and developments
9.7. KUEHNE + NAGEL
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. MOVIANTO
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.9. SOVEREIGN
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Key strategic moves and developments
9.10. VTS TRANSPORT & LOGISTICS
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
1.1. Report Description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s Five Forces Analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in number of refrigerated warehouses and expansion of the pharmaceutical sector
3.4.1.2. Government policies and initiatives to promote the cold chain logistics in the pharmaceutical sector
3.4.2. Restraints
3.4.2.1. Poor infrastructure and higher logistics costs
3.4.2.2. Environmental concerns regarding greenhouse gas emission
3.4.3. Opportunities
3.4.3.1. Surge in use of IT solutions & automated software for pharmaceutical cold chain logistics
3.4.3.2. Rise in demand for temperature-sensitive pharmaceutical drugs
3.5. COVID-19 Impact Analysis
3.6. Active Vs Passive Cold Chain Transportation
3.7. Importance of Active Vs Passive Cold Chain Transportation
3.7.1. Global Pharmaceutical Cold Chain Logistics Market, by Region, 2022-2032 ($Million)
3.8. Market Size and Forecast for Parcels, by Type, 2022-2032 ($Million)
3.9. Market Size and Forecast for Pallets, by Type, 2022-2032 ($Million)
CHAPTER 4: EUROPE PHARMACEUTICAL COLD CHAIN LOGISTICS MARKET, BY PRODUCT
4.1. Overview
4.2. Vaccines
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by country
4.3. Biologics
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by country
4.4. Specialty medications
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by country
4.5. Others
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by country
CHAPTER 5: EUROPE PHARMACEUTICAL COLD CHAIN LOGISTICS MARKET, BY TEMPERATURE TYPE
5.1. Overview
5.2. Chilled
5.2.1. Key market trends, growth factors, and opportunities
5.2.2. Market size and forecast, by country
5.3. Frozen
5.3.1. Key market trends, growth factors, and opportunities
5.3.2. Market size and forecast, by country
5.4. Room Temperature (15-25°C)
5.4.1. Key market trends, growth factors, and opportunities
5.4.2. Market size and forecast, by country
CHAPTER 6: EUROPE PHARMACEUTICAL COLD CHAIN LOGISTICS MARKET, BY MODE OF TRANSPORTATION
6.1. Overview
6.2. Railways
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country
6.3. Airways
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by region
6.4. Roadways
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by type
6.4.3. Market size and forecast, by region
6.5. Waterways
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by region
CHAPTER 7: EUROPE PHARMACEUTICAL COLD CHAIN LOGISTICS MARKET, BY COUNTRY
7.1. Overview
7.2. Europe
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. France
7.2.2.1.1. Market size and forecast, by Product
7.2.2.1.2. Market size and forecast, by Temperature Type
7.2.2.1.3. Market size and forecast, by Mode of Transportation
7.2.2.2. Germany
7.2.2.2.1. Market size and forecast, by Product
7.2.2.2.2. Market size and forecast, by Temperature Type
7.2.2.2.3. Market size and forecast, by Mode of Transportation
7.2.2.3. Italy
7.2.2.3.1. Market size and forecast, by Product
7.2.2.3.2. Market size and forecast, by Temperature Type
7.2.2.3.3. Market size and forecast, by Mode of Transportation
7.2.2.4. Spain
7.2.2.4.1. Market size and forecast, by Product
7.2.2.4.2. Market size and forecast, by Temperature Type
7.2.2.4.3. Market size and forecast, by Mode of Transportation
7.2.2.5. UK
7.2.2.5.1. Market size and forecast, by Product
7.2.2.5.2. Market size and forecast, by Temperature Type
7.2.2.5.3. Market size and forecast, by Mode of Transportation
7.2.2.6. Switzerland
7.2.2.6.1. Market size and forecast, by Product
7.2.2.6.2. Market size and forecast, by Temperature Type
7.2.2.6.3. Market size and forecast, by Mode of Transportation
7.2.2.7. Ireland
7.2.2.7.1. Market size and forecast, by Product
7.2.2.7.2. Market size and forecast, by Temperature Type
7.2.2.7.3. Market size and forecast, by Mode of Transportation
7.2.2.8. Rest of Europe
7.2.2.8.1. Market size and forecast, by Product
7.2.2.8.2. Market size and forecast, by Temperature Type
7.2.2.8.3. Market size and forecast, by Mode of Transportation
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Key player positioning ,2022
8.2. Competitive dashboard
8.2.1. Top winning strategies
CHAPTER 9: COMPANY PROFILES
9.1. A.P. MOLLER MAERSK
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. DB SCHENKER
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. DHL GROUP
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. DSV
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. GEODIS
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. H. ESSERS
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Key strategic moves and developments
9.7. KUEHNE + NAGEL
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. MOVIANTO
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.9. SOVEREIGN
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Key strategic moves and developments
9.10. VTS TRANSPORT & LOGISTICS
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
